You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

AUVI-Q Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Auvi-q patents expire, and when can generic versions of Auvi-q launch?

Auvi-q is a drug marketed by Kaleo Inc and is included in one NDA. There are eighteen patents protecting this drug.

This drug has one hundred and twelve patent family members in fourteen countries.

The generic ingredient in AUVI-Q is epinephrine. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Auvi-q

A generic version of AUVI-Q was approved as epinephrine by BPI LABS on July 29th, 2014.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AUVI-Q?
  • What are the global sales for AUVI-Q?
  • What is Average Wholesale Price for AUVI-Q?
Summary for AUVI-Q
Drug patent expirations by year for AUVI-Q
Drug Prices for AUVI-Q

See drug prices for AUVI-Q

Drug Sales Revenue Trends for AUVI-Q

See drug sales revenues for AUVI-Q

US Patents and Regulatory Information for AUVI-Q

AUVI-Q is protected by eighteen US patents.

Patents protecting AUVI-Q

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament delivery device and methods for delivering drugs to infants and children
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament delivery device and methods for delivering drugs to infants and children
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament delivery device configured to produce an audible output
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medical injector with compliance tracking and monitoring
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Medicament delivery device having an electronic circuit system
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems, and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Devices, systems and methods for medicament delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-001 Aug 10, 2012 BX RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-002 Aug 10, 2012 BX RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-001 Aug 10, 2012 BX RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-001 Aug 10, 2012 BX RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Kaleo Inc AUVI-Q epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 201739-002 Aug 10, 2012 BX RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AUVI-Q

See the table below for patents covering AUVI-Q around the world.

Country Patent Number Title Estimated Expiration
Japan 2011519712 ⤷  Sign Up
China 115658147 用于高效卷积的专用固定功能硬件 (Dedicated fixed function hardware for efficient convolution) ⤷  Sign Up
European Patent Office 4036715 MATÉRIEL DE FONCTION FIXE SPÉCIALISÉ POUR UNE CONVOLUTION EFFICACE (SPECIALIZED FIXED FUNCTION HARDWARE FOR EFFICIENT CONVOLUTION) ⤷  Sign Up
Canada 3046228 DISPOSITIF D'ADMINISTRATION DE MEDICAMENT ET PROCEDES D'ADMINISTRATION DE MEDICAMENTS A DES NOURRISSONS ET DES ENFANTS (MEDICAMENT DELIVERY DEVICE AND METHODS FOR DELIVERING DRUGS TO INFANTS AND CHILDREN) ⤷  Sign Up
Australia 2009246525 Medicament delivery device having an electronic circuit system ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.